Orsini and Paynela Partner to Expand Affordability and Copay/Coinsurance Support Programs for Rare Disease Patients

ELK GROVE VILLAGE, Ill., Sept. 3, 2025 /PRNewswire/ -- Orsini, a leader in rare disease pharmacy solutions, has partnered with Paynela, a health technology company specializing in patient affordability solutions. This collaboration will power Orsini's affordability and copay/coinsurance support programs for biopharma partners, ensuring more patients living with rare diseases can access and afford the therapies they need.

Access to therapy for rare disease patients often depends on robust copay/coinsurance assistance and financial support. By leveraging Paynela's capabilities, including AI-driven claims processing, copay/coinsurance program administration, and patient fund management, Orsini is expanding its ability to support biopharma partners with innovative, scalable solutions designed to reach underserved patient populations.

"We recognize the critical need for streamlined financial assistance solutions that help our biopharma partners reduce the burden on patients navigating complex healthcare costs," said Brandon Tom, Orsini's CEO. "Incorporating Paynela's AI-driven affordability technology into the rare disease patient journey empowers patients to more easily manage out-of-pocket costs for specialty therapies and stay connected to the care they need."

"Partnering with Orsini allows us to bring our automated affordability solutions to patients who need them most—those living with rare diseases," said Mary-Beth Macaluso, Paynela's CEO. "By streamlining traditionally manual processes like medical adjudication, we help eliminate delays that can disrupt access to life-saving therapies. Together with Orsini, we're delivering smarter, more efficient affordability solutions for our biopharma partners while ensuring patients can access the medications they need."

Orsini's affordability solutions are a key component of its broader patient support model, focused on providing holistic, compassionate care tailored to the rare disease journey.

About Paynela

Paynela is committed to connecting patients with care by reimagining every aspect of affordable care programs. The company's mission is to leverage innovation and technology to ensure that affordable care funds intended for patients reach their destination quickly, efficiently, and in full. Paynela's core services include:

• NelaClaim - AI-driven claims processing engine that delivers speed, accuracy, and efficiency of claims adjudication so that patients receive their funds faster
• NelaPay - Direct-to-patient payment options that ensure patients receive all of their funds, on their terms
• NelaView - Intuitive patient portal that empowers patients to manage and own their affordability funds directly in a simple and easy way
• NelaHub – Financial services hub that electronically identifies patients' financial assistance eligibility and delivers eligible funds directly to patient

Founded in 2024, Paynela has quickly established itself as a leader in healthcare financing innovation, helping pharmaceutical manufacturers streamline patient affordability programs while eliminating delays that historically impacted patient access to medications. The company was recognized as a 2024 AWS Generative AI Trailblazer for its groundbreaking automated solution that processes medical claims with unprecedented speed and accuracy.

For more information about Paynela, visit paynela.com.

About Orsini

Providing patients with comprehensive and compassionate care since 1987, Orsini is a leader in rare diseases and gene therapies. Orsini partners with biopharma innovators, healthcare providers and payors to support patients and their families in accessing revolutionary treatments for rare diseases. Through integrated rare disease pharmacy solutions including pharmacy distribution, patient services, clinical management and convenient home infusion services, Orsini simplifies how patients connect to advanced therapies. Orsini's high-touch care model centers on experienced and trained therapy care teams that provide personalized patient care to ensure that No Patient is Left Behind™.

Orsini holds accreditations with the Accreditation Commission for Health Care (ACHC), The Joint Commission, URAC and NABP. Orsini has earned URAC's Rare Disease Pharmacy Center of Excellence Designation and ACHC's Distinction in Rare Diseases and Orphan Drugs. For more information, visit www.orsini.com.

SOURCE Orsini